Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study reveals best diabetes drugs for your heart

NCT ID NCT05073692

Knowledge-focused Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at nearly 242,000 adults with type 2 diabetes to compare different glucose-lowering medications and their effects on heart health. The goal was to help patients and doctors choose the best treatment based on age, sex, race, and kidney function. The main focus was on major heart problems like heart attacks and strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

241,981 people

The number who actually took part.

Started

Jul 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from six large care delivery systems with integrated administrative and EHR clinical data sources (Geisinger in Pennsylvania, Henry Ford Health System in Michigan, HealthPartners Institute in Minnesota and Wisconsin, and Kaiser Permanente of Northern California, Southern California, and Hawaii) who were new users of glucose-lowering medications between 01/01/2014 and 12/31/2021.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Dispensing of either of the set of drugs being compared * No prior dispensing of nor contraindication for any of the drugs compared * Evidence of Type 2 Diabetes Mellitus diagnosis * Age 18 or older * Not currently pregnant * No evidence of dementia or short-term life expectancy from prior cancer diagnoses * History of ≥2 years of continuous health plan membership * ≥1 A1c test in the past 18 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Type 2 diabetes mellitus

Contacts and locations

Locations

  • Geisinger

    Danville, Pennsylvania, 17821, United States

  • HealthPartners Institute

    Bloomington, Minnesota, 55425, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Kaiser Permanente Hawaii

    Honolulu, Hawaii, 96817, United States

  • Kaiser Permanente Southern California

    Pasadena, California, 91101, United States

  • Romain S. Neugebauer

    Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.